These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30646017)

  • 1. Human Papillomavirus T-Cell Cross-reactivity in Cervical Cancer: Implications for Immunotherapy Clinical Trial Design.
    Helman SR; Stevanovic S; Campbell TE; Kwong MLM; Doran SL; Faquin WC; Hinrichs CS
    JAMA Netw Open; 2018 Jul; 1(3):e180706. PubMed ID: 30646017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA expressing antigenic regions of HPV 16 and 18 results in an increase in the precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and 11.
    Matijevic M; Hedley ML; Urban RG; Chicz RM; Lajoie C; Luby TM
    Cell Immunol; 2011; 270(1):62-9. PubMed ID: 21550027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6.
    Draper LM; Kwong ML; Gros A; Stevanović S; Tran E; Kerkar S; Raffeld M; Rosenberg SA; Hinrichs CS
    Clin Cancer Res; 2015 Oct; 21(19):4431-9. PubMed ID: 26429982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
    Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed.
    Shibata T; Shah S; Evans T; Coleman H; Lieblong BJ; Spencer HJ; Quick CM; Sasagawa T; Stephens OW; Peterson E; Johann D; Lu YC; Nakagawa M
    Front Immunol; 2021; 12():645299. PubMed ID: 34659195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer.
    de Vos van Steenwijk PJ; Heusinkveld M; Ramwadhdoebe TH; Löwik MJ; van der Hulst JM; Goedemans R; Piersma SJ; Kenter GG; van der Burg SH
    Cancer Res; 2010 Apr; 70(7):2707-17. PubMed ID: 20233872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial.
    Youn JW; Hur SY; Woo JW; Kim YM; Lim MC; Park SY; Seo SS; No JH; Kim BG; Lee JK; Shin SJ; Kim K; Chaney MF; Choi YJ; Suh YS; Park JS; Sung YC
    Lancet Oncol; 2020 Dec; 21(12):1653-1660. PubMed ID: 33271094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
    Wheeler CM; Castellsagué X; Garland SM; Szarewski A; Paavonen J; Naud P; Salmerón J; Chow SN; Apter D; Kitchener H; Teixeira JC; Skinner SR; Jaisamrarn U; Limson G; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Harper DM; Huh W; Hardt K; Zahaf T; Descamps D; Struyf F; Dubin G; Lehtinen M;
    Lancet Oncol; 2012 Jan; 13(1):100-10. PubMed ID: 22075170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human papillomavirus type 33 E7 peptides presented by HLA-DR*0402 to tumor-infiltrating T cells in cervical cancer.
    Höhn H; Pilch H; Günzel S; Neukirch C; Freitag K; Necker A; Maeurer MJ
    J Virol; 2000 Jul; 74(14):6632-6. PubMed ID: 10864677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element.
    Piersma SJ; Welters MJ; van der Hulst JM; Kloth JN; Kwappenberg KM; Trimbos BJ; Melief CJ; Hellebrekers BW; Fleuren GJ; Kenter GG; Offringa R; van der Burg SH
    Int J Cancer; 2008 Feb; 122(3):486-94. PubMed ID: 17955486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model.
    Jin BY; Campbell TE; Draper LM; Stevanović S; Weissbrich B; Yu Z; Restifo NP; Rosenberg SA; Trimble CL; Hinrichs CS
    JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer.
    Hasan Y; Furtado L; Tergas A; Lee N; Brooks R; McCall A; Golden D; Jolly S; Fleming G; Morrow M; Kraynyak K; Sylvester A; Arif F; Levin M; Schwartz D; Boyer J; Skolnik J; Esser M; Kumar R; Bagarazzi M; Weichselbaum R; Spiotto M
    Int J Radiat Oncol Biol Phys; 2020 Jul; 107(3):487-498. PubMed ID: 32151670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccination.
    Brotherton JML; Tabrizi SN; Phillips S; Pyman J; Cornall AM; Lambie N; Anderson L; Cummings M; Payton D; Scurry JP; Newman M; Sharma R; Saville M; Garland SM
    Int J Cancer; 2017 Oct; 141(8):1576-1584. PubMed ID: 28677147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial.
    Porras C; Tsang SH; Herrero R; Guillén D; Darragh TM; Stoler MH; Hildesheim A; Wagner S; Boland J; Lowy DR; Schiller JT; Schiffman M; Schussler J; Gail MH; Quint W; Ocampo R; Morales J; Rodríguez AC; Hu S; Sampson JN; Kreimer AR;
    Lancet Oncol; 2020 Dec; 21(12):1643-1652. PubMed ID: 33271093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.
    Muderspach L; Wilczynski S; Roman L; Bade L; Felix J; Small LA; Kast WM; Fascio G; Marty V; Weber J
    Clin Cancer Res; 2000 Sep; 6(9):3406-16. PubMed ID: 10999722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States.
    Wheeler CM; Hunt WC; Joste NE; Key CR; Quint WG; Castle PE
    J Natl Cancer Inst; 2009 Apr; 101(7):475-87. PubMed ID: 19318628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer.
    Piersma SJ; Jordanova ES; van Poelgeest MI; Kwappenberg KM; van der Hulst JM; Drijfhout JW; Melief CJ; Kenter GG; Fleuren GJ; Offringa R; van der Burg SH
    Cancer Res; 2007 Jan; 67(1):354-61. PubMed ID: 17210718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection.
    de Gruijl TD; Bontkes HJ; Stukart MJ; Walboomers JM; Remmink AJ; Verheijen RH; Helmerhorst TJ; Meijer CJ; Scheper RJ
    J Gen Virol; 1996 Sep; 77 ( Pt 9)():2183-91. PubMed ID: 8811018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
    Jenkins D
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells.
    Stevanović S; Draper LM; Langhan MM; Campbell TE; Kwong ML; Wunderlich JR; Dudley ME; Yang JC; Sherry RM; Kammula US; Restifo NP; Rosenberg SA; Hinrichs CS
    J Clin Oncol; 2015 May; 33(14):1543-50. PubMed ID: 25823737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.